tbuckley/cabot-search huggingface dataset:
Diaphragmatic Function in Cardiovascular Disease
Authors: Husam M. Salah, Lee R. Goldberg, Jeroen Molinger, G. Michael Felker, Willard Applefeld, Tienush Rassaf, Ryan J. Tedford, Michael Mirro, John G.F. Cleland, Marat Fudim
Journal: Journal of the American College of Cardiology (2022)

In addition to the diaphragm’s role as the primary respiratory muscle, it also plays an under-recognized role in cardiac function. It serves as a pump facilitating venous and lymph return, modulating left ventricular afterload hemodynamics and pericardial pressures, as well as regulating autonomic tone. Heart failure (HF) is associated with diaphragmatic changes (ie, muscle fiber atrophy and weakness, increased ratio of type I to type II muscle fibers, and altered muscle metaboreflex) that lead to diaphragmatic dysfunction with subsequent symptomatic manifestations of HF. Herein, it is proposed that targeting the diaphragm in patients with HF via inspiratory muscle training or device-based stimulation can provide a novel treatment pathway for HF. Reviewed are several potential mechanisms through which therapies targeting the diaphragm can be beneficial in HF (ie, improving preload reserve, atrial and ventricular synchrony, and metaboreflex activity; reducing pericardial restraint; and restoring diaphragm strength).
Isolated Liver Metastasis Detected by 68Ga-PSMA PET/CT in Newly Diagnosed Prostate Cancer
Authors: Hasan Önner, Halil Özer, Ahmet Volkan Çelik, Farise Yilmaz, Gonca Kara Gedik
Journal: Clinical Nuclear Medicine (2022)

Lymph nodes, bones, and liver are the most typical metastatic sites for prostate cancer. However, isolated liver metastasis from prostate cancer is extremely rare. Here, we report a 75-year-old man with newly diagnosed prostate adenocarcinoma, with isolated liver metastasis detected by 68 Ga-PSMA ( 68 Ga-prostate-specific membrane antigen) PET/CT. There was no sign of regional or distant metastases elsewhere. This case highlights the value of 68 Ga-PSMA PET/CT in detecting a very uncommon solitary liver metastasis from prostate cancer.
Noninvasive Physiologic Assessment of Cardiac Allograft Vasculopathy Is Prognostic for Post-Transplant Events
Authors: Kevin J. Clerkin, Veli K. Topkara, Maryjane A. Farr, Rashmi Jain, Paolo C. Colombo, Susan Restaino, Gabriel Sayer, Michelle Castillo, Elaine Y. Lam, Margarita Chernovolenko, Melana Yuzefpolskaya, Ersilia DeFilippis, Farhana Latif, Emmanuel Zorn, Koji Takeda, Lynne L. Johnson, Nir Uriel, Andrew J. Einstein
Journal: Journal of the American College of Cardiology (2022)
UK digital health initiatives tackle racial inequality
Authors: Udani Samarasekera
Journal: The Lancet Digital Health (2022)

In 2018, Shera Chok was at a UK conference for NHS digital leaders when she noticed something striking about the attendees—very few were women from ethnic minorities. "I remember sitting there in the morning and looking around the hall and no one looked like me", recalls Chok, interim Chief Medical Officer at NHS Digital. According to NHS and UK Government data from 2021, 77% of 1·3 million NHS staff are women and 22% are from non-White ethnic groups. "So you have people from all over the world working in the health service but if you look at the people leading the digital agenda, it's not diverse at all", Chok points out.
Canadian Spontaneous Coronary Artery Dissection Cohort Study
Authors: Jacqueline Saw, Andrew Starovoytov, Eve Aymong, Taku Inohara, Mesfer Alfadhel, Cameron McAlister, Rohit Samuel, Tejana Grewal, Johandra Argote Parolis, Tej Sheth, Derek So, Kunal Minhas, Neil Brass, Andrea Lavoie, Helen Bishop, Shahar Lavi, Colin Pearce, Suzanne Renner, Mina Madan, Robert C. Welsh, Brent M. McGrath, Ram Vijayaraghavan, Bryan Har, Reda Ibrahim, Pulkit Chaudhary, Santhi K. Ganesh, John Graham, Alexis Matteau, Giuseppe Martucci, Dennis T. Ko, Karin Humphries, GB John Mancini
Journal: Journal of the American College of Cardiology (2022)
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
Authors: Axel S Merseburger, Gerhardt Attard, Lennart Åström, Vsevolod B Matveev, Sergio Bracarda, Adil Esen, Susan Feyerabend, Elżbieta Senkus, Marta López-Brea Piqueras, Gunther Boysen, Georgia Gourgioti, Karla Martins, Simon Chowdhury
Journal: The Lancet Oncology (2022)
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
Authors: Georgina V Long, Jason J Luke, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Peter Mohr, Reinhard Dummer, Jeffrey E Gershenwald, Charles H Yoon, Xi Lawrence Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M M Eggermont, Paolo A Ascierto
Journal: The Lancet Oncology (2022)
Circulating T Cells and Cardiovascular Risk in People With and Without HIV Infection
Authors: Suman Kundu, Matthew S. Freiberg, Russell P. Tracy, Kaku A. So-Armah, John R. Koethe, Meredith S. Duncan, Hilary A. Tindle, Joshua A. Beckman, Matthew J. Feinstein, Wyatt J. McDonnell, Amy Justice, Margaret F. Doyle
Journal: Journal of the American College of Cardiology (2022)

Lower CD4+ cell count in people with HIV infection (PWH) is associated with increased cardiovascular disease (CVD) risk. Whether subsets of CD4+ T helper cells are linked with CVD is unclear. The aim of this study was to explore the association between peripherally circulating CD4+ T cell subsets and incident CVD. Data from 1,860 participants (1,270 PWH) without prevalent CVD from the VACS (Veterans Aging Cohort Study), a prospective, observational cohort of veterans with and without HIV infection, were analyzed. T cell subsets were quantified in baseline samples using flow cytometry. Incident CVD events were identified using International Classification of Diseases-9th Revision and International Classification of Diseases-10th Revision diagnosis and procedure codes. Participants were followed from baseline date (2005-2006) to the first of CVD incidence, death, or September 30, 2016. Cox proportional hazards regression was used to model associations between these T cell subsets and the risk for incident CVD while adjusting for demographics and other CVD risk factors. The median participant age at baseline was 51.6 years. Most were male (94%) and of Black race (69.1%). There were 344 incident CVD events (219 in PWH) during follow-up (median 9.8 years). In PWH, higher proportions (per SD increment) of T helper type 17 cells (adjusted HR: 1.19; 95% CI: 1.08-1.31), T effector memory cells re-expressing CD45RA (adjusted HR: 1.19; 95% CI: 1.07-1.34), and CD28null cells (adjusted HR: 1.18; 95% CI: 1.03-1.34) were significantly associated with an increased risk for incident CVD. Among those without HIV infection, no T cell subsets were significantly associated with CVD. Among PWH, T helper type 17 cells, senescent cells, and CD4+ T effector memory cells re-expressing CD45RA were significantly associated with incident CVD that was not explained by CVD risk factors.
Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillator Therapy in Patients With Tetralogy of Fallot
Authors: Victor Waldmann, Christelle Marquié, Abdeslam Bouzeman, Guillaume Duthoit, Jean-Benoit Thambo, Linda Koutbi, Alice Maltret, Jean-Luc Pasquié, Nicolas Combes, Eloi Marijon
Journal: Journal of the American College of Cardiology (2022)
Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study
Authors: Na Qin, Cheng Wang, Congcong Chen, Liu Yang, Su Liu, Jun Xiang, Yuan Xie, Shuang Liang, Jun Zhou, Xianfeng Xu, Xiaoyu Zhao, Meng Zhu, Guangfu Jin, Hongxia Ma, Juncheng Dai, Zhibin Hu, Hongbing Shen
Journal: The Lancet Oncology (2022)
Impact of Periprocedural Pulmonary Hypertension on Outcomes After Transcatheter Aortic Valve Replacement
Authors: Junichi Miyamoto, Yohei Ohno, Norihiko Kamioka, Yuji Ikari, Toshiaki Otsuka, Norio Tada, Toru Naganuma, Masahiro Yamawaki, Futoshi Yamanaka, Shinichi Shirai, Kazuki Mizutani, Minoru Tabata, Hiroshi Ueno, Kensuke Takagi, Yusuke Watanabe, Masanori Yamamoto, Kentaro Hayashida
Journal: Journal of the American College of Cardiology (2022)
Exosomes as Potential Functional Nanomaterials for Tissue Engineering
Authors: Yang Yao, Yuhuan Jiang, Jialu Song, Ruojing Wang, Zhaoping Li, Lei Yang, Weimin Wu, Luyue Zhang, Qiang Peng
Journal: Advanced Healthcare Materials (2022)

Abstract Exosomes are cell‐derived extracellular vesicles of 40–160 nm diameter, which carry numerous biomolecules and transmit information between cells. They are used as functional nanomaterials with great potential in biomedical areas, such as active agents and delivery systems for advanced drug delivery and disease therapy. In recent years, potential applications of exosomes in tissue engineering have attracted significant attention, and some critical progress has been made. This review gives a complete picture of exosomes and their applications in the regeneration of various tissues, such as the central nervous systems, kidney, bone, cartilage, heart, and endodontium. Approaches employed for modifying exosomes to equip them with excellent targeting capacity are summarized. Furthermore, current concerns and future outlook of exosomes in tissue engineering are discussed.
Retrospective analysis of sepsis in cutaneous T-cell lymphoma reveals significantly greater risk in Black patients
Authors: Madeline J Hooper, Francesca L Veon, Gail L Enriquez, Morgan Nguyen, Cameron B Grimes, Tessa M LeWitt, Yanzhen Pang, Slaton Case, Jaehyuk Choi, Joan Guitart, Michael B Burns, Xiaolong A Zhou
Journal: Journal of the American Academy of Dermatology (2022)
Prognostic role of microsatellites in melanoma and implications in the American Joint Committee on Cancer classification system: A cohort study
Authors: Constanza Riquelme-Mc Loughlin, Alejandra Sandoval-Clavijo, María Blanco de Tord, Aram Boada, Llucia Alos, Adriana García, Cristina Carrera, Josep Malvehy, Susana Puig, Agusti Toll, Sebastian Podlipnik
Journal: Journal of the American Academy of Dermatology (2022)
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
Authors: Ming-Huan Zhu, Zhen-Jing Liu, Qiong-Yue Hu, Jia-Yu Yang, Ying Jin, Na Zhu, Ying Huang, Dian-Hong Shi, Min-Jia Liu, Hong-Yang Tan, Lei Zhao, Qin-Yu Lv, Zheng-Hui Yi, Feng-Chun Wu, Ze-Zhi Li
Journal: Military Medical Research (2022)

Abstract Background Although clozapine is an effective option for treatment-resistant schizophrenia (TRS), there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine. The main purpose of this randomized, double-blind, placebo-controlled trial was to explore the amisulpride augmentation efficacy on the psychopathological symptoms and cognitive function of clozapine-resistant treatment-refractory schizophrenia (CTRS) patients. Methods A total of 80 patients were recruited and randomly assigned to receive initial clozapine plus amisulpride (amisulpride group) or clozapine plus placebo (placebo group). Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Clinical Global Impression (CGI) scale scores, Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Treatment Emergent Symptom Scale (TESS), laboratory measurements, and electrocardiograms (ECG) were performed at baseline, at week 6, and week 12. Results Compared with the placebo group, amisulpride group had a lower PANSS total score, positive subscore, and general psychopathology subscore at week 6 and week 12 ( P Bonferroni &lt; 0.01). Furthermore, compared with the placebo group, the amisulpride group showed an improved RBANS language score at week 12 ( P Bonferroni &lt; 0.001). Amisulpride group had a higher treatment response rate ( P = 0.04), lower scores of CGI severity and CGI efficacy at week 6 and week 12 than placebo group ( P Bonferroni &lt; 0.05). There were no differences between the groups in body mass index (BMI), corrected QT (QTc) intervals, and laboratory measurements. This study demonstrates that amisulpride augmentation therapy can safely improve the psychiatric symptoms and cognitive performance of CTRS patients. Conclusion This study indicates that amisulpride augmentation therapy has important clinical significance for treating CTRS to improve clinical symptoms and cognitive function with tolerability and safety. Trial registration Clinicaltrials.gov identifier- NCT03652974. Registered August 31, 2018, https://clinicaltrials.gov/ct2/show/NCT03652974
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Authors: Van K. Morris, Erin B. Kennedy, Nancy N. Baxter, Al B. Benson, Andrea Cercek, May Cho, Kristen K. Ciombor, Chiara Cremolini, Anjee Davis, Dustin A. Deming, Marwan G. Fakih, Sepideh Gholami, Theodore S. Hong, Ishmael Jaiyesimi, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H. Strickler, Sarah White, Jason A. Willis, Cathy Eng
Journal: Journal of Clinical Oncology (2022)

To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC).ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria.Doublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti-vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti-epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC; chemotherapy and anti-vascular endothelial growth factor therapy is recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for patients with previously treated BRAF V600E-mutant mCRC that has progressed after at least one previous line of therapy. Cytoreductive surgery plus systemic chemotherapy may be recommended for selected patients with colorectal peritoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recommended. Stereotactic body radiation therapy may be recommended following systemic therapy for patients with oligometastases of the liver who are not considered candidates for resection. Selective internal radiation therapy is not routinely recommended for patients with unilobar or bilobar metastases of the liver. Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are recommended. Qualifying statements with further details related to implementation of guideline recommendations are also included.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Authors: Benoit You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini Fleming, Robert Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David Cohn, Mahvish Muzaffar, David Mutch, Andrea Wahner-Hendrickson, Lainie Martin, Olivier Colomban, Robert A. Burger
Journal: Journal of Clinical Oncology (2022)

In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMination rate constant K [KELIM] score) was a predictive biomarker. Only the patients with high-risk disease (suboptimally resected stage III, or stage IV) exhibiting unfavorable KELIM score < 1.0 had overall survival (OS) benefit from bevacizumab (median: 29.7
Allogeneic stem cell transplantation for patients with myelodysplastic syndromes
Authors: Pongthep Vittayawacharin, Piyanuch Kongtim, Stefan O. Ciurea
Journal: American Journal of Hematology (2022)

Myelodysplastic syndromes (MDS) are a heterogenous group of clonal hematopoietic stem cell neoplasms primarily affecting older persons, associated with dysplastic changes of bone marrow cells, peripheral cytopenias, and various risk of leukemic transformation. Although treatment with several drugs has shown improved disease control, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for MDS. The number of patients receiving a transplant, as well as survival, have increased past years because of the use of reduce-intensity conditioning regimens (RIC) as well as the use of haploidentical donors for transplantation. With treatment-related mortality as main limitation, pre-transplant evaluation is essential to assess risks for this older group of patients. In a recent randomized study, allo-HSCT with RIC for patients >50 years old with higher-risk MDS demonstrated superiority in survival compared with hypomethylating agents. Genetic mutations have been shown to significantly impact treatment outcomes including after transplant. Recently, a transplant-specific risk score (which includes age, donor type, performance status, cytogenetic category, recipient's cytomegalovirus status, percentage of blasts, and platelet count) has shown superiority in transplantation outcome prediction, compared with previous scoring systems. Survival remains low for most patients with TP53 mutations and novel treatment strategies are needed, such as administration of natural killer cells post-transplant, as there is no clear evidence that maintenance therapy after transplantation can improve outcomes.
Error in Text
Journal: JAMA Neurology (2022)

Søren Zöga Diederichsen, MD, PhD; Kristian Steen Frederiksen, MD, PhD; Lucas Yixi Xing, MD; Ketil Jørgen Haugan, MD, PhD; Søren Højberg, MD, PhD; Axel Brandes, MD, DMSc; Claus Graff, PhD; Morten Salling Olesen, MSc, PhD; Derk Krieger, MD, PhD; Lars Køber, MD, DMSc; Jesper Hastrup Svendsen, MD, DMSc
Error in Open Access Status
Authors: Ava Liberman, Shyam Prabhakaran, Cenai Zhang, Hooman Kamel, Kamel Zhang, Zhang Liberman
Journal: JAMA Neurology (2022)

Kathryn Atherton, BA; Xudong Han, MS; Jaeyoon Chung, PhD; Jonathan D. Cherry, PhD; Zachary Baucom, MA; Nicole Saltiel, BA; Evan Nair, BA; Bobak Abdolmohammadi, BA; Madeline Uretsky, MS; Mohammed Muzamil Khan, MS; Conor Shea, BA; Shruti Durape, MBBS, MPH; Brett M. Martin, MS; Joseph N. Palmisano, MS; Kurt Farrell, PhD; Christopher J. Nowinski, PhD; Victor E. Alvarez, MD; Brigid Dwyer, MD; Daniel H. Daneshvar, MD, PhD; Douglas I. Katz, MD; Lee E. Goldstein, MD, PhD; Robert C. Cantu, MD; Neil W. Kowall, MD; Michael L. Alosco, PhD; Bertrand R. Huber, MD, PhD; Yorghos Tripodis, PhD; John F. Crary, MD, PhD; Lindsay Farrer, PhD; Robert A. Stern, PhD; Thor D. Stein, MD, PhD; Ann C. McKee, MD; Jesse Mez, MD, MS
I Talk to My Cyst
Authors: Jack Coulehan
Journal: Annals of Internal Medicine (2022)

Ad LibitumOctober 2022I Talk to My CystJack Coulehan, MDJack Coulehan, MDCenter for Medical Humanities, Compassionate Care, and Bioethics at Stony Brook University Stony Brook, New YorkSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M21-3924 Audio Reading - “I Talk to My Cyst” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “I Talk to My Cyst” by Jack Coulehan, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What I'd like to say to the cyst in my pancreas,as another MRI is battering at its door,“I would have preferred to leave you in solitude,my friend, and not subject you to anotherinvasion.” Whatever made you the watery cystyou are deserves respect. Medicine calls it a mistake,but your type—my tiny liver cyst, its kidneycounterpart—are quiet, unassuming, and lackaggression. I stumbled upon your presencea decade ago, when casting a net to discoverthe cause of an illness. It's been due diligencesince then, with doctors insisting your postureyou're embedded in doesn't understand ... Author, Article, and Disclosure InformationAuthors: Jack Coulehan, MDAffiliations: Center for Medical Humanities, Compassionate Care, and Bioethics at Stony Brook University Stony Brook, New YorkCorresponding Author: Jack Coulehan, MD; e-mail, john.[email protected].edu. PreviousarticleNextarticle Advertisement Audio Reading - “I Talk to My Cyst” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “I Talk to My Cyst” by Jack Coulehan, MD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics October 2022Volume 175, Issue 10Page: 1489 ePublished: 18 October 2022 Issue Published: October 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Prediabetes Is Associated With Increased Risk of Heart Failure Among Patients With Atrial Fibrillation
Authors: Jia-Yi Huang, Yi-Kei Tse, Hang-Long Li, Cong Chen, Chun-Ting Zhao, Ming-Ya Liu, Mei-Zhen Wu, Qing-Wen Ren, Si-Yeung Yu, Denise Hung, Xin-Li Li, Hung-Fat Tse, Gregory Y.H. Lip, Kai-Hang Yiu
Journal: Diabetes Care (2022)

OBJECTIVE To evaluate the association between prediabetes and heart failure (HF) and the association of HF with changes in glycemic status. RESEARCH DESIGN AND METHODS Patients newly diagnosed with atrial fibrillation (AF) between 2015 and 2018 were divided into three groups (normoglycemia, prediabetes, and type 2 diabetes) according to their baseline glycemic status. The primary outcome was incident HF. The Fine and Gray competing risks model was applied, with death defined as the competing event. RESULTS Among 17,943 patients with AF (mean age 75.5 years, 47% female), 3,711 (20.7%) had prediabetes, and 10,127 (56.4%) had diabetes at baseline. Over a median follow-up of 4.7 years, HF developed in 518 (14%) patients with normoglycemia, 646 (15.7%) with prediabetes, and 1,795 (17.7%) with diabetes. Prediabetes was associated with an increased risk of HF compared with normoglycemia (subdistribution hazard ratio [SHR] 1.12, 95% CI 1.03–1.22). In patients with prediabetes at baseline, 403 (11.1%) progressed to diabetes, and 311 (8.6%) reversed to normoglycemia at 2 years. Compared with remaining prediabetic, progression to diabetes was associated with an increased risk of HF (SHR 1.50, 95% CI 1.13–1.97), whereas reversion to normoglycemia was associated with a decreased risk (SHR 0.61, 95% CI 0.42–0.94). CONCLUSIONS Prediabetes was associated with an increased risk of HF in patients with AF. Compared with patients who remained prediabetic, those who progressed to diabetes at 2 years experienced an increased risk of HF, whereas those who reversed to normoglycemia incurred a lower risk of HF.